Question 1

Should I ask my doctor to switch me from Wegovy to Mounjaro for weight loss?

Accepted Answer

Probably not — the correct same-molecule obesity swap is Wegovy to Zepbound, not Wegovy to Mounjaro. Mounjaro (tirzepatide) is FDA-labeled only for type 2 diabetes, so insurance won't cover it for weight loss without a T2D diagnosis. Zepbound is the identical molecule (tirzepatide) carrying the obesity label. In SURMOUNT-5 (Aronne 2025 NEJM, PMID 40353578), tirzepatide -20.2% beat semaglutide -13.7% at 72 weeks, so asking about Zepbound is reasonable if magnitude of weight loss is your priority.

Question 2

Will insurance cover Mounjaro for obesity?

Accepted Answer

Almost never. Mounjaro's FDA label is restricted to type 2 diabetes, so commercial plans, Medicare, and Medicaid policies all require a documented T2D diagnosis (typically A1C ≥6.5% or fasting glucose ≥126 mg/dL) for coverage. Without diabetes, prior auth will deny. If you have obesity and want tirzepatide, the labeled — and far more likely covered — option is Zepbound. Some patients with diabetes and obesity get Mounjaro covered for T2D and benefit from weight loss as a downstream effect, but this is not an obesity prescription.

Question 3

Is Zepbound the correct Mounjaro equivalent for weight loss?

Accepted Answer

Yes. Mounjaro and Zepbound are the identical molecule — tirzepatide, made by Eli Lilly, at the identical doses (2.5 through 15 mg weekly). The split is purely regulatory: Mounjaro carries the T2D label (SURPASS program), Zepbound carries the obesity label (SURMOUNT-1, Jastreboff 2022 NEJM PMID 35658024) and the obstructive sleep apnea label (December 2024). Pharmacologically they are interchangeable; the brand name dictates which insurance benefit applies. For an apples-to-apples Wegovy comparison, use Zepbound.

Question 4

Which is better for a patient with both type 2 diabetes and obesity?

Accepted Answer

Tirzepatide-based therapy typically wins on magnitude. SURPASS-2 (Frías 2021 NEJM, PMID 34170647) randomized T2D patients to tirzepatide vs semaglutide 1 mg for 40 weeks; tirzepatide 15 mg produced -2.30% A1C and -11.2 kg vs semaglutide's -1.86% A1C and -5.7 kg. For a patient with both diagnoses, Mounjaro covers the T2D side (and produces real weight loss as a benefit). Wegovy retains the proven cardiovascular advantage from SELECT (Lincoff 2023 NEJM, PMID 37952131) — MACE -20% in obesity without diabetes — so high-CV-risk patients may still prefer Wegovy. The choice often comes down to which prior auth pathway is open.

Question 5

Why is the same molecule labeled twice under different brand names?

Accepted Answer

Pharmaceutical companies file separate New Drug Applications for each FDA-approved indication, often using different brand names to keep prescribing, marketing, and pricing distinct. Novo Nordisk sells semaglutide as Ozempic (T2D, subcutaneous), Wegovy (obesity, subcutaneous), and Rybelsus (T2D, oral). Eli Lilly sells tirzepatide as Mounjaro (T2D) and Zepbound (obesity + OSA). This lets each label carry indication-specific dosing schedules, pivotal trial data, and insurance benefit categories. The molecule is identical; the regulatory file is not.

Question 6

Are Wegovy and Mounjaro priced differently?

Accepted Answer

Yes, substantially. Wegovy has a manufacturer-direct cash-pay program via NovoCare at $349/mo (first 2 months) then $499/mo, available regardless of insurance status. Mounjaro has no equivalent cash tier — WAC is roughly $1,069/mo, and Lilly's savings card is restricted to commercially insured T2D patients (Medicare, Medicaid, and uninsured patients are excluded). If you don't have T2D and want tirzepatide affordably, Zepbound via LillyDirect at $349-$499/mo is the cash-pay parallel to Wegovy's NovoCare program.

Field	Wegovy	Mounjaro
FDA-approved indication	Chronic weight management; CV risk reduction in obesity	Type 2 diabetes mellitus only
Mechanism	GLP-1 receptor agonist	Dual GIP / GLP-1 receptor agonist
Weight-loss pivotal trial	-14.9% TBWL / 68 wk (STEP-1, obesity)	-11.2 kg / 40 wk (SURPASS-2, T2D 15 mg)
Same-molecule head-to-head (obesity)	Semaglutide 2.4 mg: -13.7% / 72 wk (SURMOUNT-5)	Tirzepatide 15 mg: -20.2% / 72 wk (SURMOUNT-5)
A1C reduction	Not a labeled outcome (obesity indication)	-2.30% at 15 mg / 40 wk (SURPASS-2)
Cardiovascular outcome	MACE -20% in obesity without diabetes (SELECT, 2023)	SURPASS-CVOT pending 2027
Cash price (manufacturer direct)	$349-$499/mo (NovoCare)	No cash-pay tier; ~$1,069/mo WAC (Lilly savings card, commercial only)
Same-molecule obesity equivalent	Wegovy IS the obesity-labeled semaglutide	Zepbound (tirzepatide, obesity + OSA labeled)
Pediatric labeling	Approved ages 12 and older (BMI ≥95th percentile)	Adults only (≥18 years)

Wegovy vs Mounjaro (2026): Cross-Label Confusion, Cost, Coverage

The verdict

Side-by-side comparison

Frequently asked questions